MX9301530A - Pirido(2,3-d)pirimidina-2,4(1h,3h)-diona y pirido(2,3-d)pirimidina-2(1h,3h)-ona opcionalmente substituidas. - Google Patents

Pirido(2,3-d)pirimidina-2,4(1h,3h)-diona y pirido(2,3-d)pirimidina-2(1h,3h)-ona opcionalmente substituidas.

Info

Publication number
MX9301530A
MX9301530A MX9301530A MX9301530A MX9301530A MX 9301530 A MX9301530 A MX 9301530A MX 9301530 A MX9301530 A MX 9301530A MX 9301530 A MX9301530 A MX 9301530A MX 9301530 A MX9301530 A MX 9301530A
Authority
MX
Mexico
Prior art keywords
pirimidina
pirido
optionally substituted
agents
pyrimidine
Prior art date
Application number
MX9301530A
Other languages
English (en)
Spanish (es)
Inventor
Robert Alvarez
Robert S Wilhelm
Ronnie L Chin
Bruce H Devens
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of MX9301530A publication Critical patent/MX9301530A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX9301530A 1992-03-20 1993-03-18 Pirido(2,3-d)pirimidina-2,4(1h,3h)-diona y pirido(2,3-d)pirimidina-2(1h,3h)-ona opcionalmente substituidas. MX9301530A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/855,179 US5264437A (en) 1992-03-20 1992-03-20 Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones

Publications (1)

Publication Number Publication Date
MX9301530A true MX9301530A (es) 1994-01-31

Family

ID=25320543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301530A MX9301530A (es) 1992-03-20 1993-03-18 Pirido(2,3-d)pirimidina-2,4(1h,3h)-diona y pirido(2,3-d)pirimidina-2(1h,3h)-ona opcionalmente substituidas.

Country Status (16)

Country Link
US (1) US5264437A (en:Method)
EP (2) EP1770093A1 (en:Method)
JP (1) JP3241384B2 (en:Method)
KR (1) KR100274104B1 (en:Method)
CN (1) CN1040327C (en:Method)
AU (1) AU669520B2 (en:Method)
CA (1) CA2132297C (en:Method)
FI (1) FI106960B (en:Method)
HU (2) HUT67552A (en:Method)
IL (1) IL105092A (en:Method)
MX (1) MX9301530A (en:Method)
NO (1) NO301763B1 (en:Method)
NZ (1) NZ251525A (en:Method)
TW (1) TW240226B (en:Method)
WO (1) WO1993019068A1 (en:Method)
ZA (1) ZA931945B (en:Method)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
US5817670A (en) * 1994-08-29 1998-10-06 Yamanouchi Pharmaceutical Co., Ltd. Naphthyridine derivatives and pharmaceutical compositions thereof
WO1996024350A1 (de) * 1995-02-10 1996-08-15 Schering Aktiengesellschaft Pharmazeutische präparate zur tnf-inhibition
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
JP2000119272A (ja) 1998-10-15 2000-04-25 Nippon Zoki Pharmaceut Co Ltd 新規7−アミノピリド〔2,3−d〕ピリミジン誘導体
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
HU229439B1 (hu) 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
TWI243055B (en) 2000-04-13 2005-11-11 Nippon Zoki Pharmaceutical Co Pharmaceutical composition for use in treatment of dermatitis
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
IL161661A0 (en) * 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Amide derivatives as glycogen synthase kinase 3-beta inhibitors
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
PT2074122E (pt) * 2006-09-15 2011-08-24 Pfizer Prod Inc Compostos de pirido(2,3-d)-pirimidinona e sua utilização como inibidores de pi3
WO2008084236A1 (en) * 2007-01-11 2008-07-17 Astrazeneca Ab Chemical compounds 635 : pyridopyrimidinediones as pde4 inhibitors
TW200835497A (en) * 2007-01-11 2008-09-01 Astrazeneca Ab Chemical compounds 636
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
FR2921926B1 (fr) * 2007-10-03 2009-12-04 Sanofi Aventis Derives de quinazolinedione,leur preparation et leurs applications therapeutiques.
RU2509077C2 (ru) 2008-05-27 2014-03-10 Астразенека Аб Феноксипиридиниламидные производные и их применение в лечении pde4-опосредованных болезненных состояний
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
FR2944282B1 (fr) 2009-04-09 2013-05-03 Sanofi Aventis Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
HK1218629A1 (zh) 2013-02-25 2017-03-03 Bausch Health Ireland Limited 用於结肠清洁的鸟苷酸环化酶受体激动剂
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
MX375926B (es) 2013-08-09 2025-03-07 Ardelyx Inc Compuestos y metodos para inhibir el transporte de fosfato.
EP3972599A1 (en) 2019-05-21 2022-03-30 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
US20240400560A1 (en) * 2021-09-17 2024-12-05 Shionogi & Co., Ltd. Bicyclic heterocyclic derivative having viral growth inhibitory activity and pharmaceutical composition containing same
CN113831491B (zh) * 2021-09-30 2023-03-24 南昌大学 一种嘧啶唑共价有机框架的制备方法及吸附应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649917B2 (en:Method) * 1973-12-18 1981-11-25
DE2523730A1 (de) * 1974-06-12 1976-02-12 Hisamitsu Pharmaceutical Co Pyrido eckige klammer auf 2,3-d eckige klammer zu pyrimidinonen
JPS58428B2 (ja) * 1974-07-05 1983-01-06 ヒサミツセイヤク カブシキガイシヤ シンキナ 2− オキソ −1,2,3,4− テトラヒドロピリド ( 2,3−d ) ピリミジンユウドウタイノ セイゾウホウ
EP0260817B1 (en) * 1986-08-21 1991-05-15 Pfizer Inc. Quinazolinediones and pyridopyrimidinediones
JPH07506369A (ja) * 1992-04-29 1995-07-13 エス・アール・アイ・インターナシヨナル 炎症を処置するためのデアザアミノプテリン

Also Published As

Publication number Publication date
JP3241384B2 (ja) 2001-12-25
CN1040327C (zh) 1998-10-21
FI944305L (fi) 1994-09-16
FI944305A0 (fi) 1994-09-16
EP0631580A1 (en) 1995-01-04
HU210873A9 (en) 1995-08-28
US5264437A (en) 1993-11-23
CN1078470A (zh) 1993-11-17
HU9402653D0 (en) 1994-11-28
NO943456L (no) 1994-09-16
NO301763B1 (no) 1997-12-08
TW240226B (en:Method) 1995-02-11
KR950700909A (ko) 1995-02-20
KR100274104B1 (ko) 2000-12-15
IL105092A (en) 1998-06-15
ZA931945B (en) 1994-09-18
NZ251525A (en) 1996-09-25
HUT67552A (en) 1995-04-28
AU3918693A (en) 1993-10-21
JPH07504676A (ja) 1995-05-25
CA2132297A1 (en) 1993-09-30
FI106960B (fi) 2001-05-15
IL105092A0 (en) 1993-07-08
WO1993019068A1 (en) 1993-09-30
AU669520B2 (en) 1996-06-13
NO943456D0 (no) 1994-09-16
CA2132297C (en) 2006-01-03
EP1770093A1 (en) 2007-04-04

Similar Documents

Publication Publication Date Title
MX9301530A (es) Pirido(2,3-d)pirimidina-2,4(1h,3h)-diona y pirido(2,3-d)pirimidina-2(1h,3h)-ona opcionalmente substituidas.
MX2010006212A (es) Compuestos organicos.
UY24560A1 (es) Derivados arilos de la pirimidina útiles como antagonistas 5ht2b selectivos
MY123196A (en) 1,2,3-triazolo[4,5-d]pyrimidines as p2t receptor antagonists
AR014854A1 (es) POLIMORFO CRISTALINO DEL HIDROGENOSULFATO DE CLOPIDROGREL (FORMA2) (+)-(S)-ALFA-(2-CLOROFENIL)-4,5,6,7-TETRAHIDROTIENO[3,2-C]PIRIDINIL-5-ACETATO DE METILO ,PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA QUE LO CONTIENE
DE69231522D1 (de) 1-substituierte-4-amino-1h-imidazo 4,5-c chinoline, zwischenprodukte und arzneimittel
SI1017391T1 (sl) Formulacija tablete s podaljsanim sproscanjem za zdravljenje Parkinsonove bolezni
HU0103927D0 (en) Intermediates of pyrrolo[2,3-d]pyrimidine derivatives and process for the preparation thereof
NO20014728L (no) Derivater av pyrimido[6,1-a]isokinolin-4-on
NO20075232L (no) Fremgangsmate for fremstilling av pyrido[2,3-d]pyrimidin-7-on og 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1 H)-on derivater
HUP0400229A2 (hu) Triaza-spiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
HUP0500332A3 (en) Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
CA2239705A1 (en) Quinazoline-4-one ampa antagonists
HUP0500328A3 (en) Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)-one derivatives, their use and pharmaceutical compositions containing them
HUP0303480A2 (hu) 4-(2-Butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il)-pirazolo-[1,5-a]-1,3,5-triazin-származékok, mint CRF-antagonisták, és ezeket tartalmazó gyógyszerkészítmények
MY143089A (en) Pyrido[2,3-d] pyrimidine derivatives, preparation thereof, therapeutic use thereof
WO2005044818A3 (en) Imidazo[1,2-a]pyridine anxiolytics
AP9901532A0 (en) 2-Methoxyphenylpiperazine derivatives.
DE69911785D1 (de) Triazolo[4,5-d]pyrimidin-verbindungen
GT200500319A (es) Algunos metabolitos derivados de [1,4]diazepino[6,7,1-ij]quinolina y metodos para la preparacion y usos de los mismos.
PT1044203E (pt) Derivados epimericos 3' do k-252a
MA71617A (fr) Formes cristallines de (6s,7s)-6-fluoro-7-(2-fluoro-5-méthylphényl)-3-(tétrahydro-2h-pyran-4-yl)-5,6,7,8-tétrahydropyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione
ATE223412T1 (de) Antikonvulsiv und antiallergisch/antiasthmatisch wirkende pyrazolo(3,4-d)pyrimidine
ECSP992939A (es) Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmaceuticas
WO2023034965A3 (en) Co-crystals

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees